Jane Street’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Jane Street’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,628	Closed	-$600	–	9466
2023 Q1	$600	Sell	10,628 -260	-2%	-$15	﹤0.01%	8892
2022 Q4	$512	Buy	10,888 +400	+4%	+$24	﹤0.01%	8989
2022 Q3	$1K	Sell	10,488 -84	-0.8%	-$10	﹤0.01%	9560
2022 Q2	$2K	Sell	10,572 -750	-7%	-$171	﹤0.01%	9484
2022 Q1	$5K	Sell	11,322 -2,228	-16%	-$1.88K	﹤0.01%	10132
2021 Q4	$24K	Buy	+13,550	New	+$24.9K	﹤0.01%	9757

Other funds holding SABSW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Jane Street's SABSW Position: Q2 2023 in Review

Jane Street sold out of SAB Biotherapeutics Warrant (SABSW) in Q2 2023, closing a stake of 10,628 shares — an estimated $600 sold.

Jane Street first reported a position in SABSW in Q4 2021 and held it in 6 quarters. The position peaked at $24K in Q4 2021. 10 funds tracked by Wall St. Rank hold SABSW as of Q2 2023.

Jane Street reported no remaining SAB Biotherapeutics Warrant position as of Q2 2023 after selling out during the quarter.
Jane Street sold 10,628 SAB Biotherapeutics Warrant shares in Q2 2023, an estimated $600.
Jane Street first reported a position in SAB Biotherapeutics Warrant in Q4 2021 and held it in 6 quarters.
Jane Street's SAB Biotherapeutics Warrant position peaked at $24K in Q4 2021.
10 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2023.

Based on Jane Street's 13F filing for Q2 2023, filed 14 Aug 2023.